Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' VANOOSTEROM AT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 94 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. CASSIDY J; DIRIX L; BISSETT D; REIGNER B; GRIFFIN T; ALLMAN D; OSTERWALDER B; VANOOSTEROM AT
      A PHASE-I STUDY OF CAPECITABINE IN COMBINATION WITH ORAL LEUCOVORIN IN PATIENTS WITH INTRACTABLE SOLID TUMORS

      Clinical cancer research
    2. WYNENDAELE W; PARIDAENS R; CHRISTIAENS MR; VANDENBOGAERT W; VANOOSTEROM AT
      SEQUENTIAL DOXORUBICINE (DOX) AND DOCETAXEL (DOC) AS NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED BREAST-CANCER (LABC) - A PILOT-STUDY

      European journal of cancer
    3. SCHRIJVERS D; PRONK L; HIGHLEY M; BRUNO M; LOCCITONELLI D; DEBRUIJN E; VANOOSTEROM AT; VERWEIJ J; VERMORKEN JB
      SEQUENCE-DEPENDENT PHARMACOKINETICS (PK) OF IFOSFAMIDE (I) COMBINED WITH DOCETAXEL (D)

      European journal of cancer
    4. BOFFETTA P; FICHTINGERSCHEPMAN AMJ; WEIDERPASS E; VANDIJKKNIJNENBURG HCM; STOTER G; VANOOSTEROM AT; KEIZER HJ; FOSSA SD; KALDOR J; ROY P
      CISPLATIN - DNA-ADDUCTS AND PROTEIN-BOUND PLATINUM IN BLOOD OF TESTICULAR CANCER-PATIENTS

      Anti-cancer drugs
    5. HOSSFELD DK; VANOOSTEROM AT
      PROF. DR. VANDERSCHUEREN,E. - OBITUARY

      Annals of oncology
    6. VANOOSTEROM AT; KRZEMIENLECKI K; NIELSEN OS; JUDSON I; MOURIDSEN HT; SVANCAROVA L; WOLL P; SPOONER D; HERMANS C; VANGLABBEKE M; VERWEIJ J
      FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS)

      Annals of oncology
    7. LECESNE A; JUDSON J; CROWTHER D; SOMERS R; TURSZ T; KEIZER J; VANHOESEL D; BLAY Y; FRISCH J; VANGLABBEKE M; VANOOSTEROM AT; VERWEIJ J
      IS OBTENTION OF PARTIAL-RESPONSE (PR) IN FRONT-LINE CHEMOTHERAPY CRITICAL TO IMPROVE OUTCOME OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) PATIENTS (PTS)

      Annals of oncology
    8. WYNENDAELE W; DERUA R; HOYLAERTS MF; PAWINSKI A; WAELKENS E; DEBRUIJN EA; MERLEVEDE W; PARIDAENS R; VANOOSTEROM AT
      VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) - PLASMA IS THE PLACE TO BE

      Annals of oncology
    9. THODTMANN R; DEPENBROCK H; DUMEZ H; OHNMACHT U; BLATTER J; VANOOSTEROM AT; HANAUSKE AR
      PHASE-I STUDY OF DIFFERENT SEQUENCES OF MTA (LY231514) IN COMBINATIONWITH CISPLATIN IN PATIENTS WITH SOLID TUMORS

      Annals of oncology
    10. PAWINSKIL A; LOUWERENS M; TONELLI D; VANOOSTEROM AT; VERWEIJ J
      A PHASE-I STUDY OF TAXOTERE (T) AND GEMZAR (G) IN PATIENTS WITH ADVANCED SOLID TUMORS

      Annals of oncology
    11. THERASSE P; EISENHAUER E; WANDERS J; VERWEIJ J; VANGLABBEKE M; VANOOSTEROM AT; KAPLAN RS; CHRISTIAN MC; GWYTHER S; ARBUCK SG
      EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED

      Annals of oncology
    12. THODTMANN R; KEMMERICH M; DEPENBROCK H; HEUSER A; VANOOSTEROM AT; HANAUSKE AR
      A CLINICAL-PHASE-I TRIAL OF TOPOTECAN IN COMBINATION WITH CARBOPLATININ PATIENTS WITH ADVANCED SOLID TUMORS

      Annals of oncology
    13. HIGHLEY MS; SCHRIJVERS D; ARDIET C; VANOOSTEROM AT; DEBRUIJN EA
      PHARMACOKINETICS OF THE MITOMYCIN KW-2149 - GENERATION OF THE ACTIVE METABOLITE M-18

      Annals of oncology
    14. BRUNO R; HILLE D; RIVA A; VIVIER N; HUINNINK WWTB; VANOOSTEROM AT; KAYE SB; VERWEIJ J; FOSSELLA FV; VALERO V; RIGAS JR; SEIDMAN AD; CHEVALLIER B; FUMOLEAU P; BURRIS HA; RAVCLIN PM; SHEINER LB
      POPULATION PHARMACOKINETICS PHARMACODYNAMICS OF DOCETAXEL IN PHASE-IISTUDIES IN PATIENTS WITH CANCER/

      Journal of clinical oncology
    15. PRONK LC; SCHRIJVERS D; SCHELLENS JHM; DEBRUIJN EA; PLANTING AST; LOCCITONELLI D; GROULT V; VERWEIJ J; VANOOSTEROM AT
      DOCETAXEL AND IFOSFAMIDE IN PATIENTS WITH ADVANCED SOLID TUMORS - RESULTS OF A PHASE-I STUDY

      Seminars in oncology
    16. DEWIT R; COLLETTE L; SYLVESTER R; DEMULDER PHM; SLEIJFER DT; HUININK WWT; KAYE SB; VANOOSTEROM AT; BOVEN E; STOTER G
      SERUM ALPHA-FETOPROTEIN SURGE AFTER THE INITIATION OF CHEMOTHERAPY FOR NONSEMINOMATOUS TESTICULAR CANCER HAS AN ADVERSE PROGNOSTIC-SIGNIFICANCE

      British Journal of Cancer
    17. BONTENBAL M; ANDERSSON M; WILDIERS J; COCCONI G; JASSEM J; PARIDAENS R; ROTMENSZ N; SYLVESTER R; MOURIDSEN HT; KLIJN JGM; VANOOSTEROM AT
      DOXORUBICIN VS EPIRUBICIN, REPORT OF A 2ND-LINE RANDOMIZED PHASE-II PHASE-III STUDY IN ADVANCED BREAST-CANCER/

      British Journal of Cancer
    18. BAKKER M; DROZ JP; HANAUSKE AR; VERWEIJ J; VANOOSTEROM AT; GROEN HJM; PACCIARINI MA; DOMENIGONI L; VANWEISSENBRUCH F; PIANEZZOLA E; DEVRIES EGE
      BROAD PHASE-II AND PHARMACOKINETIC STUDY OF METHOXY-MORPHOLINO DOXORUBICIN (FCE 23762-MMRDX) IN NON-SMALL-CELL LUNG-CANCER, RENAL-CANCER AND OTHER SOLID TUMOR PATIENTS

      British Journal of Cancer
    19. PRONK LC; SCHRIJVERS D; SCHELLENS JHM; DEBRUIJN EA; PLANTING AST; LOCCITONELLI D; GROULT V; VERWEIJ J; VANOOSTEROM AT
      PHASE-I STUDY ON DOCETAXEL AND IFOSFAMIDE IN PATIENTS WITH ADVANCED SOLID TUMORS

      British Journal of Cancer
    20. VANDENBRANDE J; SCHRIJVERS D; VROMAN P; PROVE A; VANSCHIL P; BECQUART D; VANMARCK E; VANOOSTEROM AT
      LATE RELAPSE OF A NONSEMINOMATOUS GERM-CELL TUMOR FROM RESIDUAL MATURE TERATOMA

      Acta Clinica Belgica
    21. VERWEIJ J; NIELSEN OS; THERASSE P; VANOOSTEROM AT
      THE USE OF A SYSTEMIC THERAPY CHECKLIST IMPROVES THE QUALITY OF DATA-ACQUISITION AND RECORDING IN MULTICENTER TRIALS - A STUDY OF THE EORTCSOFT-TISSUE AND BONE SARCOMA GROUP

      European journal of cancer
    22. DEWIT R; PAWINSKY A; STOTER G; VANOOSTEROM AT; FOSSA SD; PARIDAENS R; SVEDBERG A; DEMULDER PHM
      EORTC PHASE-II STUDY OF DAILY ORAL LINOMIDE IN METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH GOOD PROGNOSTIC FACTORS

      European journal of cancer
    23. PAWINSKI A; VANOOSTEROM AT; DEWIT R; FOSSA S; CROLES J; SVEDBERG A; LENTZ MA; DEMULDER PHM
      AN EORTC PHASE-II STUDY OF THE EFFICACY AND SAFETY OF LINOMIDE IN THETREATMENT OF ADVANCED RENAL-CELL CARCINOMA

      European journal of cancer
    24. WANDERS J; VANOOSTEROM AT; GORE M; CALVERT AH; HUININK WWT; HANSEN HH; WISSEL P; HANAUSKE AR
      A PHASE-II STUDY WITH GI147211 IN OVARIAN-CANCER

      European journal of cancer
    25. DIRIX LY; LIBURA M; LIBURA J; VERMEULEN PB; DEBRUIJN EA; VANOOSTEROM AT
      IN-VITRO TOXICITY STUDIES WITH MITOMYCINS AND BLEOMYCIN ON ENDOTHELIAL-CELLS

      Anti-cancer drugs
    26. DEBOECK G; VANCAUWENBERGHE K; EGGERMONT AMM; VANOOSTEROM AT; DEBRUIJN EA
      CE DETERMINATION OF THE CYTOKINE TNF-ALPHA IN PERFUSION SAMPLES FROM CANCER-PATIENTS

      HRC. Journal of high resolution chromatography
    27. DEBOECK G; VANCAUWENBERGHE K; EGGERMONT AMM; VANOOSTEROM AT; DEBRUIJN EA
      DETERMINATION OF MELPHALAN AND HYDROLYSIS PRODUCTS IN BODY-FLUIDS BY GC-MS

      HRC. Journal of high resolution chromatography
    28. HIGHLEY MS; SCHRIJVERS D; VANOOSTEROM AT; HARPER PG; MOMERENCY G; VANCAUWENBERGHE K; MAES RAA; DEBRUIJN EA; EDELSTEIN MB
      ACTIVATED OXAZAPHOSPHORINES ARE TRANSPORTED PREDOMINANTLY BY ERYTHROCYTES

      Annals of oncology
    29. GHEUENS EEO; VANDERHEYDEN SAM; ELST HE; VANOOSTEROM AT; DEBRUIJN EA
      COMPARISON OF DAUNORUBICIN AND FLUO-3 FOR DETECTION OF MULTIDRUG-RESISTANCE IN HUMAN TUMOR-CELLS

      Cancer detection and prevention
    30. VERMEULEN PB; LIBURA M; LIBURA J; ONEILL PJ; VANDAM P; VANMARCK E; VANOOSTEROM AT; DIRIX LY
      INFLUENCE OF INVESTIGATOR EXPERIENCE AND MICROSCOPIC FIELD SIZE ON MICROVESSEL DENSITY IN NODE-NEGATIVE BREAST-CARCINOMA

      Breast cancer research and treatment
    31. TIERNEY JF; STEWART LA; PARMAR MKB; FLETCHER CDM; JONES G; MOSSERI V; PATEL M; DEELVIRA MCR; SOUHAMI RL; SYLVESTER R; TURSZ T; ALVEGARD TA; SIGURDSSON H; ANTMAN K; BACCHI M; BAKER LH; BENJAMIN RS; BRADY MF; BRAMWELL V; BUI BN; EDMONSON JH; LEYVRAZ S; OMURA GA; ROUESSE J; RYAN L; VANOOSTEROM AT; YANG JC
      ADJUVANT CHEMOTHERAPY FOR LOCALIZED RESECTABLE SOFT-TISSUE SARCOMA OFADULTS - METAANALYSIS OF INDIVIDUAL DATA

      Lancet
    32. VERMEULEN PB; DIRIX LY; LIBURA J; VANHOOLST IF; VANMARCK E; VANOOSTEROM AT
      CORRELATION OF THE FRACTIONS OF PROLIFERATING TUMOR AND ENDOTHELIAL-CELLS IN BREAST AND COLORECTAL ADENOCARCINOMA IS INDEPENDENT OF TUMOR HISTIOTYPE AND MICROVESSEL DENSITY

      Microvascular research
    33. KUMARSINGH S; VERMEULEN PB; WEYLER J; SEGERS K; WEYN B; VANDAELE A; DIRIX LY; VANOOSTEROM AT; VANMARCK E
      EVALUATION OF TUMOR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA

      Journal of pathology
    34. DIRIX LY; VERMEULEN PB; PAWINSKI A; PROVE A; BENOY I; DEPOOTER C; MARTIN M; VANOOSTEROM AT
      ELEVATED LEVELS OF THE ANGIOGENIC CYTOKINES BASIC FIBROBLAST GROWTH-FACTOR AND VASCULAR ENDOTHELIAL GROWTH-FACTOR IN SERA OF CANCER-PATIENTS

      British Journal of Cancer
    35. PUNT CJA; VOEST EE; TUENI E; VANOOSTEROM AT; BACKX A; DEMULDER PHM; HECQUET B; LUCAS C; GERARD B; BLEIBERG H
      PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER

      British Journal of Cancer
    36. DEWIT R; SYLVESTER R; TSITSA C; DEMULDER PHM; SLEYFER DT; HUININK WWT; KAYE SB; VANOOSTEROM AT; BOVEN E; VERMEYLEN K; STOTER G
      TUMOR-MARKER CONCENTRATION AT THE START OF CHEMOTHERAPY IS A STRONGERPREDICTOR OF TREATMENT FAILURE THAN MARKER HALF-LIFE - A STUDY IN PATIENTS WITH DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER

      British Journal of Cancer
    37. VERMEULEN PB; DIRIX LY; MARTIN M; LEMMENS J; VANOOSTEROM AT
      SERUM BASIC FIBROBLAST GROWTH-FACTOR AND VASCULAR ENDOTHELIAL GROWTH-FACTOR IN METASTATIC RENAL-CELL CARCINOMA TREATED WITH INTERFERON ALFA-2B

      Journal of the National Cancer Institute
    38. HILLNER BE; VANOOSTEROM AT
      OPTIMAL CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A COST-UTILITY COMPARISON - PARTIAL PROCEEDINGS OF A SATELLITE SYMPOSIUM TO THE 4TH EUROPEAN WINTER ONCOLOGY CONGRESS, MERIBEL, FRANCE, 22 JANUARY 1995 - FOREWORD

      PharmacoEconomics
    39. VANSCHIL PEY; VANLOOK R; VANCALSTER ELY; VANOOSTEROM AT; HAUBEN EI
      STERNAL RESECTION FOR PRIMARY PRESTERNAL AND RETROSTERNAL MEDIASTINALLIPOSARCOMA

      European journal of cardio-thoracic surgery
    40. EGELMEERS A; DIRIX LY; LYCZEK J; DEBRUIJN EA; VANOOSTEROM AT; SCALLIET P
      THE INFLUENCE OF HYPOXIA ON THE CYTOTOXICITY OF CONCOMITANT KW-2149 AND IONIZING IRRADIATION IN CHINESE-HAMSTER FIBROBLASTS

      Anti-cancer drugs
    41. DIRIX LY; VERMEULEN PB; FIERENS H; DESCHEPPER B; CORTHOUTS B; VANOOSTEROM AT
      LONG-TERM RESULTS OF CONTINUOUS TREATMENT WITH RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH METASTATIC CARCINOID-TUMORS - AN ANTIANGIOGENIC EFFECT

      Anti-cancer drugs
    42. DIRIX LY; VERMEULEN PB; HUBENS G; BENOY I; MARTIN M; DEPOOTER C; VANOOSTEROM AT
      SERUM BASIC FIBROBLAST GROWTH-FACTOR AND VASCULAR ENDOTHELIAL GROWTH-FACTOR AND TUMOR-GROWTH KINETICS IN ADVANCED COLORECTAL-CANCER

      Annals of oncology
    43. DIRIX LY; VERMEULEN PB; VANOOSTEROM AT
      MICROVASCULAR COUNT AND PROGNOSIS IN COLORECTAL-CANCER

      Journal of clinical oncology
    44. PARIZEL PM; DIRIX L; VANDENWEYNGAERT D; LAMBERT JR; SCALLIET P; VANOOSTEROM AT; DESCHEPPER AM
      DEEP CEREBRAL INVASION BY BASAL-CELL CARCINOMA OF THE SCALP

      Neuroradiology
    45. VERMEULEN PB; ROLAND L; MERTENS V; VANMARCK E; DEBRUIJN EA; VANOOSTEROM AT; DIRIX LY
      CORRELATION OF INTRATUMORAL MICROVESSEL DENSITY AND P53 PROTEIN OVEREXPRESSION IN HUMAN COLORECTAL ADENOCARCINOMA

      Microvascular research
    46. MOMERENCY G; VANCAUWENBERGHE K; HIGHLEY MS; HARPER PG; VANOOSTEROM AT; DEBRUIJN EA
      PARTITIONING OF IFOSFAMIDE AND ITS METABOLITES BETWEEN RED-BLOOD-CELLS AND PLASMA

      Journal of pharmaceutical sciences
    47. VERMEULEN PB; DIRIX LY; VANMARCK E; VANOOSTEROM AT
      HIGH ENDOTHELIAL-CELL PROLIFERATION INDEX AND HIGH MICROVESSEL DENSITY IN VASCULAR HOTSPOTS SUGGEST AN ACTIVE ANGIOGENIC PROCESS IN HUMAN COLORECTAL ADENOCARCINOMAS

      British Journal of Cancer
    48. DEPOOTER CM; VANOOSTEROM AT; SCALLIET PG; MAES RA; DEBRUIJN EA
      CORRELATION OF THE RESPONSE TO CISPLATIN OF HUMAN OVARIAN-CANCER CELL-LINES, ORIGINATING FROM ONE TUMOR BUT WITH DIFFERENT SENSITIVITY, WITH THE RECOVERY OF DNA-ADDUCTS

      Biochemical pharmacology
    49. VANDAM PA; TJALMA W; WEYLER J; VANOOSTEROM AT; BUYTAERT P
      ULTRARADICAL DEBULKING OF EPITHELIAL OVARIAN-CANCER WITH THE ULTRASONIC SURGICAL ASPIRATOR - A PROSPECTIVE RANDOMIZED TRIAL

      American journal of obstetrics and gynecology
    50. VERWEIJ J; MOURIDSEN HT; NIELSSEN OS; WOLL PJ; SOMERS R; VANOOSTEROM AT; VANGLABBEKE M; TURSZ T
      THE PRESENT STATE-OF-THE-ART IN CHEMOTHERAPY FOR SOFT-TISSUE SARCOMASIN ADULTS - THE EORTC POINT-OF-VIEW

      Critical reviews in oncology/hematology
    51. VANOOSTEROM AT; SCHRIJVERS D
      RECENT DEVELOPMENTS IN THE BIOLOGY AND MANAGEMENT OF ADVANCED BLADDER-CANCER

      European journal of cancer
    52. PAWINSKI A; VANOOSTEROM AT; DEMULDER PHM; STOTER G; SVEDBERG A
      THE EFFICACY AND SAFETY OF LINOMIDE IN THE TREATMENT OF RENAL-CELL CARCINOMA [RCC] - AN EORTC PHASE-II STUDY

      European journal of cancer
    53. VANOOSTEROM AT; FAVALLI G; KOBIESKA A; PAWINSKY A; SAHMOUD T; PECORELLI S
      PHASE-II STUDY OF CISPLATIN (P), VINBLASTINE (V) AND BLEOMYCIN (B) INRECURRENT OR ADVANCED DYSGERMINOMA (D)

      European journal of cancer
    54. DEPOOTER CH; SCALLIET P; VANOOSTEROM AT
      CISPLATIN, CARBOPLATIN AND IRRADIATION IN HUMAN OVARIAN-CANCER CELLS

      European journal of cancer
    55. VANOOSTEROM AT; MOURIDSEN HT; DOMBERNOWSKI I; NIELSEN OS; VANPOTTELSBERGHE C; VANGLABBEKE M; TURSZ T
      PRELIMINARY-REPORT OF A RANDOMIZED PHASE-II STUDY COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN ADVANCED SOFT-TISSUE SARCOMA PATIENTS (PTS) FAILING FIRST-LINE ANTHRACYCLINES

      European journal of cancer
    56. HIGHLEY MS; MOMERENCY G; VANCAUWENBERGHE K; VANOOSTEROM AT; SCHRYVERS D; DEBRUIJN EA; MAES RA; HARPER PG
      UPTAKE OF IFOSFAMIDE (IF) AND ITS METABOLITES BY ERYTHROCYTES (E)

      European journal of cancer
    57. PRONK L; SHRIJVERS D; LOCCITONELLI D; VERWEIJ J; VANOOSTEROM AT
      PHASE-I STUDY OF DOCETAXEL AND IFOSFAMIDE IN PATIENTS WITH ADVANCED SOLID TUMORS

      European journal of cancer
    58. HIGHLEY MS; PATTYN G; LAMBRECHTS H; DEBRUIJN EA; VANOOSTEROM AT; HARPER PG
      ERYTHROCYTES AND THE DISTRIBUTION OF MITOMYCIN-C (MMC)

      European journal of cancer
    59. VANOOSTEROM AT
      THE TAXOIDS A NEW GROUP OF ACTIVE COMPOUNDS AGAINST MANY CANCER TYPES

      European journal of cancer
    60. VANOOSTEROM AT; SCHRIJVERS D
      DOCETAXEL (TAXOTERE(R)), A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .2. CLINICAL-EXPERIENCE (VOL 6, PG 356, 1995)

      Anti-cancer drugs
    61. VANOOSTEROM AT; SCHRIIVERS D
      DOCETAXEL (TAXOTERE(R)), A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .2. CLINICAL-EXPERIENCE

      Anti-cancer drugs
    62. VERMEULEN PB; VERHOEVEN D; HUBENS G; VANMARCK E; GOOVAERTS G; HUYGHE M; DEBRUIJN EA; VANOOSTEROM AT; DIRIX LY
      MICROVESSEL DENSITY, ENDOTHELIAL-CELL PROLIFERATION AND TUMOR-CELL PROLIFERATION IN HUMAN COLORECTAL ADENOCARCINOMAS

      Annals of oncology
    63. VANOOSTEROM AT; VERWEIJ J
      NEW DRUGS FOR THE TREATMENT OF SARCOMAS

      Hematology/oncology clinics of North America
    64. VANHOOF VO; JANSEN H; SCHEPENS P; MARTIN M; BLOCKX P; PROVE AM; VANOOSTEROM AT; LEPOUTRE LG
      COMPARISON OF 3 METHODS TO QUANTIFY SERUM BONE ALKALINE-PHOSPHATASE

      Journal of bone and mineral research
    65. SORBER M; DEBRUIJN EA; KOCKX M; BULTINCK J; VANOOSTEROM AT; DENIS L
      EFFECTS AND SYSTEMIC UPTAKE OF THE NEW MITOMYCIN-C ANALOG KW-2149 IN BEAGLE DOGS AFTER INTRAVESICAL ADMINISTRATION

      Urological research
    66. VANOOSTEROM AT
      DOCETAXEL (TAXOTERE) - AN EFFECTIVE AGENT IN THE MANAGEMENT OF 2ND-LINE BREAST-CANCER

      Seminars in oncology
    67. HIGHLEY MS; MOMERENCY G; VANCAUWENBERGHE K; VANOOSTEROM AT; DEBRUIJN EA; MAES RAA; BLAKE P; MANSI J; HARPER PG
      FORMATION OF CHLOROETHYLAMINE AND 1,3-OXAZOLIDINE-2-ONE FOLLOWING IFOSFAMIDE ADMINISTRATION IN HUMANS

      Drug metabolism and disposition
    68. DEJONGE MJA; VANDAM PA; VANMARCK E; PROVE A; VANOOSTEROM AT
      PRIMARY EXTRAUTERINE MULLERIAN ADENOSARCOMA OF THE PERITONEUM

      Gynecologic oncology
    69. HELLEMANS P; VANDAM PA; GEYSKENS M; VANOOSTEROM AT; BUYTAERT P; VANMARCK E
      IMMUNOHISTOCHEMICAL STUDY OF TOPOISOMERASE II-ALPHA EXPRESSION IN PRIMARY DUCTAL CARCINOMA OF THE BREAST

      Journal of Clinical Pathology
    70. VERMEULEN PB; DIRIX LY; PELGRIMS G; VANOOSTEROM AT
      5-FLUOROURACIL LEUCOVORIN/INTERFERON ALPHA-2A IN PATIENTS WITH ADVANCED COLORECTAL-CANCER/

      Cancer
    71. LAGARDE P; GHEUENS EEO; DEPOOTER CMJ; DEBRUIJN EA; VANDERHEYDEN S; CHOMY F; VANOOSTEROM AT; SCALLIET PG
      IN-VITRO EFFECTS OF PIRACETAM ON THE RADI OSENSITIVITY OF HYPOXIC CELLS (ADAPTATION OF MTT ASSAY TO HYPOXIC CONDITIONS)

      Bulletin du cancer
    72. HELLEMANS P; VANDAM PA; WEYLER J; VANOOSTEROM AT; BUYTAERT P; VANMARCK E
      PROGNOSTIC VALUE OF BCL-2 EXPRESSION IN INVASIVE BREAST-CANCER

      British Journal of Cancer
    73. VERMEULEN PB; VERHOEVEN D; FIERENS H; HUBENS G; GOOVAERTS G; VANMARCK E; DEBRUIJN EA; VANOOSTEROM AT; DIRIX LY
      MICROVESSEL QUANTIFICATION IN PRIMARY COLORECTAL-CARCINOMA - AN IMMUNOHISTOCHEMICAL STUDY

      British Journal of Cancer
    74. DEMULDER PHM; OOSTERHOF GON; BOUFFIOUX C; VANOOSTEROM AT; VERMEYLEN K; SYLVESTER R
      EORTC(30885) RANDOMIZED PHASE-III STUDY WITH RECOMBINANT INTERFERON-ALPHA AND RECOMBINANT INTERFERON-ALPHA AND INTERFERON-GAMMA IN PATIENTSWITH ADVANCED RENAL-CELL CARCINOMA

      British Journal of Cancer
    75. VERMEULEN PB; LIBURA J; LIBURA M; HELLEMANS PWJ; VANMARCK E; VANOOSTEROM AT; DIRIX LY
      TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST-CARCINOMA

      Journal of the National Cancer Institute
    76. MOMERENCY G; VANCAUWENBERGHE K; SLEE PHTJ; VANOOSTEROM AT; DEBRUIJN EA
      THE DETERMINATION OF CYCLOPHOSPHAMIDE AND ITS METABOLITES IN BLOOD-PLASMA AS STABLE TRIFLUOROACETYL DERIVATIVES BY ELECTRON-CAPTURE CHEMICAL-IONIZATION GAS-CHROMATOGRAPHY MASS-SPECTROMETRY

      Biological mass spectrometry
    77. VANDIEST PJ; BAAK JPA; BRUGGHE J; VANDEBURG MEL; VANOOSTEROM AT; NEIJT JP
      QUANTITATIVE PATHOLOGICAL FEATURES AS PREDICTORS OF LONG-TERM SURVIVAL IN PATIENTS WITH ADVANCED OVARIAN-CANCER TREATED WITH CISPLATIN

      International journal of gynecological cancer
    78. DIRIX LY; GHEUENS EEO; VANDERHEYDEN S; VANOOSTEROM AT; DEBRUIJN EA
      CYTOTOXIC ACTIVITY OF A-L-GLUTAMYLAMINO)-ETHYL)DITHIO)ETHYL)-MITOMYCIN-C AND METABOLITES IN CELL-LINES WITH DIFFERENT RESISTANCE PATTERNS

      Anti-cancer drugs
    79. MOMERENCY G; VANCAUWENBERGHE K; DEBRUIJN EA; VANOOSTEROM AT; HIGHLEY MS; HARPER PG
      DETERMINATION OF IPHOSPHAMIDE AND 7 METABOLITES IN BLOOD-PLASMA, AS STABLE TRIFLUOROACETYL DERIVATIVES, BY ELECTRON-CAPTURE CHEMICAL-IONIZATION GC-MS

      HRC. Journal of high resolution chromatography
    80. DIRIX LY; VANMEERBEECK J; SCHRIJVERS D; CORTHOUTS B; PROVE A; VANMARCK E; VERMEIRE P; VANOOSTEROM AT
      A PHASE-II TRIAL OF DOSE-ESCALATED DOXORUBICIN AND IFOSFAMIDE MESNA IN PATIENTS WITH MALIGNANT MESOTHELIOMA

      Annals of oncology
    81. VANHOESEL OGCM; VERWEIJ J; CATIMEL G; CLAVEL M; KERBRAT P; VANOOSTEROM AT; KERGER J; TURSZ T; VANGLABBEKE M; VANPOTTELSBERGHE C; LEBAIL N; MOURIDSEN H
      PHASE-II STUDY WITH DOCETAXEL (TAXOTERE(R)) IN ADVANCED SOFT-TISSUE SARCOMAS OF THE ADULT

      Annals of oncology
    82. VANGERVEN JMA; HOVESTADT A; MOLL JWB; RODENBURG CJ; SPLINTER TAW; VANOOSTEROM AT; KEIZER L; DROGENDIJK TE; GROENHOUT CM; VECHT CJ; NEIJT JP
      THE EFFECTS OF AN ACTH-[4-9] ANALOG ON DEVELOPMENT OF CISPLATIN NEUROPATHY IN TESTICULAR CANCER - A RANDOMIZED TRIAL

      Journal of neurology
    83. VANDAM PA; COPPENS M; VANOOSTEROM AT; VANMARCK E; BUYTAERT P
      IS THERE AN INCREASED RISK FOR TUMOR DISSEMINATION USING ULTRASONIC SURGICAL ASPIRATION IN PATIENTS WITH VULVAR CARCINOMA

      European journal of obstetrics, gynecology, and reproductive biology
    84. DIRIX LY; SCHRIJVERS D; DRUWE P; VANDENBRANDE J; VERHOEVEN D; VANOOSTEROM AT
      PULMONARY TOXICITY AND BLEOMYCIN

      Lancet
    85. DEMULDER PHM; STERNBERG CN; VANOOSTEROM AT; FOSSA SD
      THE APPLICATION OF HEMATOPOIETIC GROWTH-FACTORS IN ADVANCED TRANSITIONAL-CELL CARCINOMA OF THE URINARY-TRACT

      Seminars in oncology
    86. SORBE BG; HOGBERG T; GLIMELIUS B; SCHMIDT M; WERNSTEDT L; HANSEN O; SORENSEN BT; RAISANEN I; VANOOSTEROM AT; DEBRUIJN KM
      A RANDOMIZED, MULTICENTER STUDY COMPARING THE EFFICACY AND TOLERABILITY OF TROPISETRON, A NEW 5-HT3 RECEPTOR ANTAGONIST, WITH A METOCLOPRAMIDE-CONTAINING ANTIEMETIC COCKTAIL IN THE PREVENTION OF CISPLATIN-INDUCED EMESIS

      Cancer
    87. STEWARD WP; VANTONGELEN K; VERWEIJ J; THOMAS D; VANOOSTEROM AT
      CHEMOTHERAPY ADMINISTRATION AND DATA-COLLECTION IN AN EORTC COLLABORATIVE GROUP - CAN WE TRUST THE RESULTS

      European journal of cancer
    88. DROZ JP; VANOOSTEROM AT
      TREATMENT OPTIONS IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - A WAGER ON THE FUTURE - A REVIEW

      European journal of cancer
    89. VANGLABBEKE M; VANOOSTEROM AT; STEWARD W; VERWEIJ J; MOURIDSEN H
      SELECTION OF LARGE AND OBJECTIVELY MEASURABLE TARGET LESIONS IN EORTCPHASE-II TRIALS - IMPACT ON RECRUITMENT AND RESPONSE RATE

      European journal of cancer
    90. STERNBERG CN; DEMULDER PHM; VANOOSTEROM AT; FOSSA SD; GIANNARELLI D; SOEDIRMAN JR
      ESCALATED M-VAC CHEMOTHERAPY AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF) IN PATIENTS WITH ADVANCED UROTHELIAL TRACT TUMORS

      Annals of oncology
    91. PROVE AM; DIRIX LY; SCHRIJVERS D; VANOOSTEROM AT
      THE MANAGEMENT OF OVARIAN-CANCER

      Annals of oncology
    92. VANDEVRIE W; VANDERHEYDEN SAM; GHEUENS EEO; BIJMA AM; DEBRUIJN EA; MARQUET RL; VANOOSTEROM AT; EGGERMONT AMM
      DRUG-RESISTANCE IN RAT COLON-CANCER CELL-LINES IS ASSOCIATED WITH MINOR CHANGES IN SUSCEPTIBILITY TO CYTOTOXIC-CELLS

      Cancer immunology and immunotherapy
    93. VANSCHIL PEY; COLPAERT CGA; VANLOOK R; VANOOSTEROM AT; VANMARCK EAE; REHER SW; SCHOOFS ELG
      PRIMARY MEDIASTINAL LEIOMYOSARCOMA

      The thoracic and cardiovascular surgeon
    94. VERHOEVEN D; VANMARCK E; VANOOSTEROM AT
      RADIATION-THERAPY FOR IN-SITU OR LOCALIZED BREAST-CANCER

      The New England journal of medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/21 alle ore 22:17:18